Physician profile
Jeffrey Nold
NPI 1053488841
$1,448.15
in general payments reported to CMS, 2019-2025
23 companies · $141 in 2025
The $141 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $102 · 2021: $237 · 2022: $37.79 · 2023: $141 · 2024: $263 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $165.82 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $146.92 | 2021 | |
| Tris Pharma INC | $132.53 | 2019-2025 | Dyanavel Xr |
| Pfizer INC. | $132.32 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $128.06 | 2019-2023 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $93.27 | 2024-2025 | Flumist Quadrivalent |
| Kaleo, INC. | $76.73 | 2019 | |
| Merck Sharp & Dohme LLC | $68.22 | 2024-2025 | Gardasil 9, Proquad, M-M-R II |
| Shire North American Group INC | $67.77 | 2019 | |
| Glaxosmithkline, LLC. | $54.08 | 2019-2024 | Bexsero |
| Adlon Therapeutics L.P. | $46.08 | 2019-2020 | |
| Cranial Technologies, INC | $45.03 | 2019-2023 | Doc Band |
| Cumberland Pharmaceuticals, INC. | $43.20 | 2019-2023 | Kristalose |
| Vertical Pharmaceuticals, LLC | $35.86 | 2019-2024 | Relexxii |
| Corium, LLC | $33.47 | 2024 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $28.56 | 2025 | Neffy |
| Seqirus USA INC | $28.53 | 2021-2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $24.91 | 2024 | |
| Vyne Pharmaceuticals INC. | $23.56 | 2020 | |
| Aimmune Therapeutics, INC. | $18.88 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.74 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.40 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $17.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.